Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model

Bart G. Jones, Robert E. Sealy, Sherri L. Surman, Allen Portner, Charles J. Russell, Karen S. Slobod, Philip R. Dormitzer, John Devincenzo, Julia L. Hurwitz

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Respiratory syncytial virus (RSV) is the cause of significant morbidity and mortality among infants, and despite decades of research there remains no licensed vaccine. SeVRSV is a Sendai virus (SeV)-based live intranasal vaccine that expresses the full length RSV fusion (F) gene. SeV is the murine counterpart of human parainfluenza virus type 1. Given that the target population of SeVRSV is young infants, we questioned whether maternal antibodies typical of this age group would inhibit SeVRSV vaccine efficacy. After measuring SeV- and RSV-specific serum neutralizing antibody titers in human infants, we matched these defined titers in cotton rats by the passive transfer of polyclonal or monoclonal antibody products. Animals were then vaccinated with SeVRSV followed by a 3 month rest period to allow passively transferred antibodies to wane. Animals were finally challenged with RSV to measure the de novo vaccine-induced immune responses. Despite the presence of passively-transferred serum neutralizing antibodies at the time of vaccination, SeVRSV induced immune responses that were protective against RSV challenge. The data encourage advancement of SeVRSV as a candidate vaccine for the protection of children from morbidity and mortality caused by RSV.

Original languageEnglish (US)
Pages (from-to)3264-3273
Number of pages10
JournalVaccine
Volume32
Issue number26
DOIs
StatePublished - May 30 2014

Fingerprint

Respiratory Syncytial Virus Vaccines
Sendai virus
Respiratory Syncytial Viruses
maternal immunity
Mothers
vaccines
Vaccines
viruses
Antibodies
Human parainfluenza virus 1
Neutralizing Antibodies
neutralizing antibodies
morbidity
Sigmodontinae
Sigmodon
child welfare
Morbidity
Child Mortality
immune response
Health Services Needs and Demand

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Jones, B. G., Sealy, R. E., Surman, S. L., Portner, A., Russell, C. J., Slobod, K. S., ... Hurwitz, J. L. (2014). Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model. Vaccine, 32(26), 3264-3273. https://doi.org/10.1016/j.vaccine.2014.03.088

Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model. / Jones, Bart G.; Sealy, Robert E.; Surman, Sherri L.; Portner, Allen; Russell, Charles J.; Slobod, Karen S.; Dormitzer, Philip R.; Devincenzo, John; Hurwitz, Julia L.

In: Vaccine, Vol. 32, No. 26, 30.05.2014, p. 3264-3273.

Research output: Contribution to journalArticle

Jones, BG, Sealy, RE, Surman, SL, Portner, A, Russell, CJ, Slobod, KS, Dormitzer, PR, Devincenzo, J & Hurwitz, JL 2014, 'Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model', Vaccine, vol. 32, no. 26, pp. 3264-3273. https://doi.org/10.1016/j.vaccine.2014.03.088
Jones BG, Sealy RE, Surman SL, Portner A, Russell CJ, Slobod KS et al. Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model. Vaccine. 2014 May 30;32(26):3264-3273. https://doi.org/10.1016/j.vaccine.2014.03.088
Jones, Bart G. ; Sealy, Robert E. ; Surman, Sherri L. ; Portner, Allen ; Russell, Charles J. ; Slobod, Karen S. ; Dormitzer, Philip R. ; Devincenzo, John ; Hurwitz, Julia L. / Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model. In: Vaccine. 2014 ; Vol. 32, No. 26. pp. 3264-3273.
@article{7f267cab2b194a17a03df01f46b16627,
title = "Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model",
abstract = "Respiratory syncytial virus (RSV) is the cause of significant morbidity and mortality among infants, and despite decades of research there remains no licensed vaccine. SeVRSV is a Sendai virus (SeV)-based live intranasal vaccine that expresses the full length RSV fusion (F) gene. SeV is the murine counterpart of human parainfluenza virus type 1. Given that the target population of SeVRSV is young infants, we questioned whether maternal antibodies typical of this age group would inhibit SeVRSV vaccine efficacy. After measuring SeV- and RSV-specific serum neutralizing antibody titers in human infants, we matched these defined titers in cotton rats by the passive transfer of polyclonal or monoclonal antibody products. Animals were then vaccinated with SeVRSV followed by a 3 month rest period to allow passively transferred antibodies to wane. Animals were finally challenged with RSV to measure the de novo vaccine-induced immune responses. Despite the presence of passively-transferred serum neutralizing antibodies at the time of vaccination, SeVRSV induced immune responses that were protective against RSV challenge. The data encourage advancement of SeVRSV as a candidate vaccine for the protection of children from morbidity and mortality caused by RSV.",
author = "Jones, {Bart G.} and Sealy, {Robert E.} and Surman, {Sherri L.} and Allen Portner and Russell, {Charles J.} and Slobod, {Karen S.} and Dormitzer, {Philip R.} and John Devincenzo and Hurwitz, {Julia L.}",
year = "2014",
month = "5",
day = "30",
doi = "10.1016/j.vaccine.2014.03.088",
language = "English (US)",
volume = "32",
pages = "3264--3273",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "26",

}

TY - JOUR

T1 - Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model

AU - Jones, Bart G.

AU - Sealy, Robert E.

AU - Surman, Sherri L.

AU - Portner, Allen

AU - Russell, Charles J.

AU - Slobod, Karen S.

AU - Dormitzer, Philip R.

AU - Devincenzo, John

AU - Hurwitz, Julia L.

PY - 2014/5/30

Y1 - 2014/5/30

N2 - Respiratory syncytial virus (RSV) is the cause of significant morbidity and mortality among infants, and despite decades of research there remains no licensed vaccine. SeVRSV is a Sendai virus (SeV)-based live intranasal vaccine that expresses the full length RSV fusion (F) gene. SeV is the murine counterpart of human parainfluenza virus type 1. Given that the target population of SeVRSV is young infants, we questioned whether maternal antibodies typical of this age group would inhibit SeVRSV vaccine efficacy. After measuring SeV- and RSV-specific serum neutralizing antibody titers in human infants, we matched these defined titers in cotton rats by the passive transfer of polyclonal or monoclonal antibody products. Animals were then vaccinated with SeVRSV followed by a 3 month rest period to allow passively transferred antibodies to wane. Animals were finally challenged with RSV to measure the de novo vaccine-induced immune responses. Despite the presence of passively-transferred serum neutralizing antibodies at the time of vaccination, SeVRSV induced immune responses that were protective against RSV challenge. The data encourage advancement of SeVRSV as a candidate vaccine for the protection of children from morbidity and mortality caused by RSV.

AB - Respiratory syncytial virus (RSV) is the cause of significant morbidity and mortality among infants, and despite decades of research there remains no licensed vaccine. SeVRSV is a Sendai virus (SeV)-based live intranasal vaccine that expresses the full length RSV fusion (F) gene. SeV is the murine counterpart of human parainfluenza virus type 1. Given that the target population of SeVRSV is young infants, we questioned whether maternal antibodies typical of this age group would inhibit SeVRSV vaccine efficacy. After measuring SeV- and RSV-specific serum neutralizing antibody titers in human infants, we matched these defined titers in cotton rats by the passive transfer of polyclonal or monoclonal antibody products. Animals were then vaccinated with SeVRSV followed by a 3 month rest period to allow passively transferred antibodies to wane. Animals were finally challenged with RSV to measure the de novo vaccine-induced immune responses. Despite the presence of passively-transferred serum neutralizing antibodies at the time of vaccination, SeVRSV induced immune responses that were protective against RSV challenge. The data encourage advancement of SeVRSV as a candidate vaccine for the protection of children from morbidity and mortality caused by RSV.

UR - http://www.scopus.com/inward/record.url?scp=84900441477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900441477&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2014.03.088

DO - 10.1016/j.vaccine.2014.03.088

M3 - Article

C2 - 24721531

AN - SCOPUS:84900441477

VL - 32

SP - 3264

EP - 3273

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 26

ER -